Skip to main content
SpringerLink
Log in

Denosumab

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1292 Accesses

Abstract

Denosumab (Prolia®, Xgeva®, Amgen) is a human recombinant IgG2k antibody directed to receptor activator of nuclear factor kappa-B ligand (RANKL), and thus inhibiting its interaction with the specific RANK receptor. The blocking interferes with formation, function, and survival of osteoclasts, which are essential for bone resorption.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Denosumab (Prolia®) BLA 125320 FDA Medical Review, 2010

    Google Scholar 

  2. Denosumab (Prolia® WC500093526 EMA Summary of product characteristics. Annex I 2012

    Google Scholar 

  3. Denosumab (Prolia®) Product Information, Amgen 2013

    Google Scholar 

  4. Denosumab (Xgeva®) WC500110381 EMA Summary of product characteristics. Annex I 2012

    Google Scholar 

  5. Denosumab (Xgeva®) Product Information, Amgen 2013

    Google Scholar 

  6. Stopeck AT, Lipton A, Body J–J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 35:5132–5139

    Article  Google Scholar 

  7. Fizazi K, Carducci M, Smith M et al (2012) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 377:813–822

    Article  Google Scholar 

  8. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132

    Article  CAS  PubMed  Google Scholar 

  9. Horwoll E, Teglbjærg CS, Langdahl BL et al (2012) A randomized, placebo- controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161–3169

    Article  Google Scholar 

  10. Jones H, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696

    Article  CAS  PubMed  Google Scholar 

  11. Castellano D, Sepulveda JM, Garçia-Escobar I et al (2011) The role of RANK-Ligand inhibition in cancer: the story of Denosumab. Oncologist 16:136–145

    Article  CAS  PubMed  Google Scholar 

  12. Baron R, Ferrari S, Russell GG (2011) Denosumab and bisphosphonates: different mechanism of action and effects. Bone 48:677–692

    Article  CAS  PubMed  Google Scholar 

  13. Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporosis Int 22:435–446

    Article  CAS  Google Scholar 

  14. Denosumab background information for ACRHD, Amgen 13 Aug. 2009

    Google Scholar 

  15. Prolia® (denosumab) Product Monograph, Amgen Canada Apr 2011

    Google Scholar 

  16. Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase 3 trials. Eur J Cancer 48:3082–3092

    Article  CAS  PubMed  Google Scholar 

  17. Lewiecki EM Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. (2011) Drug, Healthcare and Patient Safety 3:79–91

    Google Scholar 

  18. Xgeva® (denosumab) Product Monograph, Amgen Canada Aug 2012

    Google Scholar 

  19. Smith MR, Saad F, Coleman R et al (2012) Denosumab as bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet 379:39–46

    Article  CAS  PubMed  Google Scholar 

  20. Denosumab (Xgeva®) FDA ODAC Briefing Document BLA 125320/28, Feb 2012

    Google Scholar 

  21. Steger GG and Bartsch R (2011) Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 3: 233-243

    Google Scholar 

  22. Lei S, Shiying Y (2012) Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases. A systematic review and meta-analysis. Am J Clin Oncol doi. doi:10.1097/COC.0b013e31824be20e

    Google Scholar 

  23. Knoop KA, Kumar N, Butler BR et al (2009) RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol. 183:5738–5747

    Article  CAS  PubMed  Google Scholar 

  24. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Therap 84:548–558

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 59 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Denosumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_17

Download citation

Publish with us

Policies and ethics

Search

Navigation